Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 22, 2022 - Issue 9
Submit an article Journal homepage
717
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Hesitancies in primary headaches treatments

William David Wells-Gatnika Department of Clinical and Molecular Medicine, Sapienza University, Rome, ItalyView further author information
,
Fidel Dominique Festin Ambata Department of Clinical and Molecular Medicine, Sapienza University, Rome, ItalyView further author information
&
Paolo Martellettia Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy;b Regional Referral Headache Center, Emergency Medicine Unit, Sant’Andrea University Hospital, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6556-4128View further author information
ORCID Icon
Pages 733-735 | Received 06 Jun 2022, Accepted 23 Aug 2022, Published online: 01 Sep 2022

References

  • Stovner LJ, Hagen K, Linde M, et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022 Apr 12;23:34. PMID: 35410119; PMCID: PMC9004186.
  • Steiner TJ, Jensen R, Katsarava Z, et al. Lifting the burden: the global campaign against headache. Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. J Headache Pain. 2021 Jul 21;22:78. PMID: 34289806; PMCID: PMC8293530.
  • Lenz B, Katsarava Z, Gil-Gouveia R, et al. European headache federation and lifting the burden: the global campaign against headache. Headache service quality evaluation: implementation of quality indicators in primary care in Europe. J Headache Pain. 2021 Apr;28(22):33. PMID: 33910500; PMCID: PMC8080333.
  • Sacco S, Amin FA, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022 Jun 11;23:67. PMID: 35690723; PMCID: PMC9188162.
  • [cited 2022 Jun 1]. Available from: https://www.ema.europa.eu/en/documents/smop/questions-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_en.pdf
  • [cited 2022 Jun 1]. Available from: https://www.cdc.gov/chronicdisease/about/costs/index.htm
  • Kardas P, van Boven JFM, Pinnock H, et al. ENABLE collaborators. Disparities in European healthcare system approaches to maintaining continuity of medication for non-communicable diseases during the COVID-19 outbreak. Lancet Reg Health Eur. 2021 May;4:100099. Epub 2021 Apr 14. PMID: 33875981; PMCID: PMC8046426.
  • Ambat FDF, Bentivegna E, Martelletti P. Novel migraine therapies may reduce public and personal disadvantages for people with migraine. BioDrugs. 2022 May;36:337–339. PMID: 35575969; PMCID: PMC9109201.
  • Sacco S, Lampl C, Maassen van den Brink A, Burden and Attitude to Resistant and Refractory (BARR) Study Group, et al. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain. 2021 May 18;22:39. PMID: 34006218; PMCID: PMC8130435.
  • Luciani M, Negro A, Spuntarelli V, et al. Evaluating and managing severe headache in the emergency department. Expert Rev Neurother. 2021 Mar;21:277–285. Epub 2021 Jan 4. PMID: 33297780.
  • Negro A, Spuntarelli V, Sciattella P, et al. Rapid referral for headache management from emergency department to headache centre: four years data. J Headache Pain. 2020 Mar 14;21(1):25. PMID: 32169031; PMCID: PMC7071765.
  • Wenzel R, Smith TR, Clark AS. Cluster headache: opportunities for pharmacists to improve care. J Pharm Pract. 2020 Oct 9:897190020964297. 2022 Apr;35;281–288. PMID: 33034236.
  • Booth S, Parsons R, Sunderland B, et al. Managing migraine with over-the-counter provision of triptans: the perspectives and readiness of Western Australian community pharmacists. PeerJ. 2019 Dec;16(7):e8134. PMID: 31871835; PMCID: PMC6921984.
  • Steiner TJ, Birbeck GL, Jensen RH, et al. The Global Campaign turns 18: a brief review of its activities and achievements. J Headache Pain. 2022 Apr;21(23):49. PMID: 35448941; PMCID: PMC9022610.
  • Bentivegna E, Tassorelli C, De Icco R, et al. Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. Expert Rev Neurother. 2022 Mar;22:237–243. PMID: 35196206.
  • Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting calcitonin-gene-related-peptide with the Disease-Modifying Migraine Drugs (DMMDs). J Headache Pain. 2019 May 23;20:60. PMID: 31122205; PMCID: PMC6734307.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.